Teva and its Cephalon affiliate have been handed fines totaling €60.5m ($72m) over a historic “pay-for-delay” arrangement covering Cephalon’s Provigil (modafinil) that violated EU antitrust rules and caused “substantial harm to EU patients and healthcare systems by keeping prices high.”
The fine is the culmination of a near 10-year investigation by the European Commission that began in April 2011, weeks before Teva signed a definitive agreement to acquire Cephalon and...